Literature DB >> 6583026

Human tissue distribution of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA).

D J Stewart, G Zhengang, K Lu, N Savaraj, L G Feun, M Luna, R S Benjamin, M J Keating, T L Loo.   

Abstract

Concentrations of AMSA were determined by HPLC in autopsy tissue samples from five patients who had received the drug antemortem. Relative organ concentrations of AMSA varied from patient to patient; however, concentrations were generally highest in gallbladder, liver, and kidney, while low levels were generally but not invariably found in lung, testicle, muscle, fat, spleen, bladder, pancreas, colon, prostate, and brain. One patient with ventricular fibrillation and seizures had high tissue AMSA concentrations in myocardium, but low concentrations in brain. Another patient with seizures during treatment had high brain concentrations of AMSA. Relative organ concentrations were similar to those found in mice, except that mice have high AMSA concentration in their spleens whereas our patients did not, even when the spleen was infiltrated with leukemic cells. High tissue concentrations of AMSA were still present 2 weeks after treatment. AMSA concentration was lower in a renal oncocytoma (1.1 micrograms/g) than in surrounding kidney (2.4 micrograms/g).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6583026     DOI: 10.1007/bf00254602

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Selective localization of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in B 16 melanoma.

Authors:  D D Shoemaker; S S Legha; R L Cysyk
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

2.  Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.

Authors:  S S Legha; J U Gutterman; S W Hall; R S Benjamin; M A Burgess; M Valdivieso; G P Bodey
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

3.  The pharmacologic disposition of 4'-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats.

Authors:  R L Cysyk; D Shoemaker; R H Adamson
Journal:  Drug Metab Dispos       Date:  1977 Nov-Dec       Impact factor: 3.922

4.  Phase II study of AMSA in patients with metastatic malignant melanoma.

Authors:  A M Houghton; F Camacho; R Wittes; C W Young
Journal:  Cancer Treat Rep       Date:  1981 Jan-Feb

5.  Lethal activity and kinetic response of cultured human cells to 4'-(9-acridinylamino)methanesulfon-m-anisidine.

Authors:  B Drewinko; L Y Yang; B Barlogie
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

6.  Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.

Authors:  D D Von Hoff; K Howser; P Gormley; R A Bender; D Glaubiger; A S Levine; R C Young
Journal:  Cancer Treat Rep       Date:  1978-10

7.  Multiple ventricular extrasystoles following administration of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA).

Authors:  G Falkson
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar

8.  Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).

Authors:  D D Von Hoff; D Elson; G Polk; C Coltman
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar

9.  Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.

Authors:  P P Sordillo; G B Magill; R J Gralla; R B Golbey
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

10.  Initial experience with AMSA as single agent treatment against malignant lymphoproliferative disorders.

Authors:  F Cabanillas; S S Legha; G P Bodey; E J Freireich
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

View more
  5 in total

1.  Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.

Authors:  E M Cornford; D Young; J W Paxton
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.

Authors:  D J Stewart; D Grewaal; M D Redmond; N Z Mikhael; V A Montpetit; R Goel; R M Green
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Human autopsy-tissue distribution of menogaril and its metabolites.

Authors:  D J Stewart; D Grewaal; R M Green; R Goel; N Mikhael; V A Montpetit; D Redmond; R Earhart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.